272 related articles for article (PubMed ID: 27057669)
21. The B-cell receptor pathway: a critical component of healthy and malignant immune biology.
Zhong Y; Byrd JC; Dubovsky JA
Semin Hematol; 2014 Jul; 51(3):206-18. PubMed ID: 25048784
[TBL] [Abstract][Full Text] [Related]
22. Targeting the B cell receptor pathway in chronic lymphocytic leukemia.
Davids MS; Brown JR
Leuk Lymphoma; 2012 Dec; 53(12):2362-70. PubMed ID: 22616724
[TBL] [Abstract][Full Text] [Related]
23. Inhibitors of B-cell receptor signaling for patients with B-cell malignancies.
Choi MY; Kipps TJ
Cancer J; 2012; 18(5):404-10. PubMed ID: 23006944
[TBL] [Abstract][Full Text] [Related]
24. [Inhibition of B cell receptor signaling: a first targeted therapeutic approach for chronic lymphocytic leukemia and other B cell lymphomas].
Mráz M; Doubek M; Mayer J
Klin Onkol; 2013; 26(3):179-85. PubMed ID: 23763320
[TBL] [Abstract][Full Text] [Related]
25. Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies.
ten Hacken E; Burger JA
Pharmacol Ther; 2014 Dec; 144(3):338-48. PubMed ID: 25050922
[TBL] [Abstract][Full Text] [Related]
26. Targeting the B cell receptor pathway in non-Hodgkin lymphoma.
Valla K; Flowers CR; Koff JL
Expert Opin Investig Drugs; 2018 Jun; 27(6):513-522. PubMed ID: 29855199
[TBL] [Abstract][Full Text] [Related]
27. The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling.
Lorenzo-Herrero S; Sordo-Bahamonde C; Bretones G; Payer ÁR; González-Rodríguez AP; González-García E; Pérez-Escuredo J; Villa-Álvarez M; Núñez LE; Morís F; Gonzalez S; López-Soto A
Front Immunol; 2019; 10():2455. PubMed ID: 31681329
[TBL] [Abstract][Full Text] [Related]
28. Signaling pathways activated by antigen-receptor engagement in chronic lymphocytic leukemia B-cells.
Efremov DG; Gobessi S; Longo PG
Autoimmun Rev; 2007 Dec; 7(2):102-8. PubMed ID: 18035318
[TBL] [Abstract][Full Text] [Related]
29. B-cell receptor signaling as a driver of lymphoma development and evolution.
Niemann CU; Wiestner A
Semin Cancer Biol; 2013 Dec; 23(6):410-21. PubMed ID: 24060900
[TBL] [Abstract][Full Text] [Related]
30. Targeting Signaling Pathways in Chronic Lymphocytic Leukemia.
Muggen AF; Singh SP; Hendriks RW; Langerak AW
Curr Cancer Drug Targets; 2016; 16(8):669-688. PubMed ID: 27055580
[TBL] [Abstract][Full Text] [Related]
31. Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia.
Herman SE; Barr PM; McAuley EM; Liu D; Wiestner A; Friedberg JW
Leukemia; 2013 Aug; 27(8):1769-73. PubMed ID: 23385377
[No Abstract] [Full Text] [Related]
32. Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.
Burger JA
Curr Hematol Malig Rep; 2012 Mar; 7(1):26-33. PubMed ID: 22105489
[TBL] [Abstract][Full Text] [Related]
33. Signal transduction inhibitors in chronic lymphocytic leukemia.
Ma S; Rosen ST
Curr Opin Oncol; 2011 Nov; 23(6):601-8. PubMed ID: 21892084
[TBL] [Abstract][Full Text] [Related]
34. Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition.
Slinger E; Thijssen R; Kater AP; Eldering E
Leukemia; 2017 Dec; 31(12):2601-2607. PubMed ID: 28462919
[TBL] [Abstract][Full Text] [Related]
35. The alternative transcript of CD79b is overexpressed in B-CLL and inhibits signaling for apoptosis.
Cragg MS; Chan HT; Fox MD; Tutt A; Smith A; Oscier DG; Hamblin TJ; Glennie MJ
Blood; 2002 Nov; 100(9):3068-76. PubMed ID: 12384401
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders.
Castillo JJ; Treon SP; Davids MS
Cancer J; 2016; 22(1):34-9. PubMed ID: 26841015
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells.
Gobessi S; Laurenti L; Longo PG; Carsetti L; Berno V; Sica S; Leone G; Efremov DG
Leukemia; 2009 Apr; 23(4):686-97. PubMed ID: 19092849
[TBL] [Abstract][Full Text] [Related]
38. Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives.
Seiler T; Dreyling M
Expert Opin Investig Drugs; 2017 Aug; 26(8):909-915. PubMed ID: 28661188
[TBL] [Abstract][Full Text] [Related]
39. B-cell receptor pathway modulators in NHL.
Blum KA
Hematology Am Soc Hematol Educ Program; 2015; 2015():82-91. PubMed ID: 26637705
[TBL] [Abstract][Full Text] [Related]
40. The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action.
Chen R; Tsai J; Thompson PA; Chen Y; Xiong P; Liu C; Burrows F; Sivina M; Burger JA; Keating MJ; Wierda WG; Plunkett W
Blood Cancer J; 2021 Mar; 11(3):57. PubMed ID: 33714981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]